Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - milprosa™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women up to and including 34 years of age. limitation of use efficacy in women 35 years of age and older has not been established. milprosa is contraindicated in women with: - known sensitivity to progesterone or any of the ingredients of milprosa [see description (11)] - undiagnosed vaginal bleeding - severe hepatic impairment or disease - known or suspected malignancy of the breast - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events risk summary milprosa is indicated to support embryo implantation and early pregnancy as part of an assisted reproductive technology treatment program in vitro fertilization (ivf) with or without intracytoplasmic sperm injection (icsi) and embryo transfer for infertile women. maternal risks a

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

symbion pharmacy services pty ltd - zinc oxide -

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

ovelle limited - zinc oxide; castor oil - ointment - 7.5 %w/w + 50 percent weight/weight - zinc products

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam 7.5 mg - temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. benzodiazepines may cause fetal harm when administered to a pregnant woman. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. reproduction studies in animals with temazepam were performed in rats and rabbits. in a perinatal- postnatal study in rats, oral doses of 60 mg/kg/day resul

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cvs pharmacy - avobenzone 3.0%, homosalate 15.0%, octisalate 5.0%, octocrylene 10%, oxybenzone 3.0% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see ​directions ​), decreases the risk of skin cancer and early skin aging caused by the sun - ​​on damaged or broken skin - rash occurs.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cvs pharmacy - avobenzone 2.7%, homosalate 8.0%, octisalate 5.0%, octocrylene 3.5%, oxybenzone 4.0% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see ​directions ), decreases the risk of skin cancer and early skin aging caused by the sun on damaged or broken skin if rash occurs.​

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

amcol health & beauty solutions, inc. dba - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm) - sunscreen sunscreen sunscreen sunscreen sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging cause by the sun.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - acetaminophen and codeine phosphate tablets, usp are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets, usp for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] controlled substance acetaminophen and codeine phosphate tablets, usp contain codeine. codeine in combination with acetaminophen, is a schedule iii controlled substance. abuse acetaminophen and codeine phosphate tablets, usp contain codeine, a substance with a high potential for abuse similar to other opioids, including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. acetaminophen and codeine phosphate tablets, usp can be abused and is subject to misuse, addiction, and criminal diversi

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cvs pharmacy, inc - octinoxate 6.0%, zinc oxide 3.0% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun on damaged or broken skin  and ask a doctor if rash occurs